SCHEMBL6349201

SCHEMBL6349201

Cc1ccccc1NC(=O)C(C)(C)O

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 1/20 0.70
PDK2 Q15119 1/20 0.70
PDK3 Q15120 1/20 0.70
PDK4 Q16654 1/20 0.70
NPC1 O15118 2/20 0.62
RAB9A P51151 2/20 0.62
HPGD P15428 5/20 0.60
ALDH1A1 P00352 2/20 0.60
POLB P06746 2/20 0.55
ALOX12 P18054 1/20 0.51
HTT P42858 2/20 0.50
EPHX1 P07099 1/20 0.50
KDM4E B2RXH2 1/20 0.50
LMNA P02545 1/20 0.50
MAPK1 P28482 1/20 0.50
HSD17B10 Q99714 1/20 0.50
DDX3X O00571 1/20 0.50
KDM4C Q9H3R0 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL397003 0.86 PDK1 (0.67) PDK1PDK2PDK3PDK4NPC1
SCHEMBL26623837 0.83 PDK1 (0.73) PDK1PDK2PDK3PDK4NPC1
SCHEMBL8347800 0.83 PDK1 (0.63) PDK1PDK2PDK3PDK4NPC1
SCHEMBL11173223 0.81 PDK1 (0.61) PDK1PDK2PDK3PDK4NPC1
SCHEMBL11245698 0.81 PDK1 (0.61) PDK1PDK2PDK3PDK4NPC1
SCHEMBL28121437 0.81 RAB9A (0.62) PDK1PDK2PDK3PDK4NPC1
SCHEMBL914296 0.81 PDK1 (0.70) PDK1PDK2PDK3PDK4NPC1
SCHEMBL6824411 0.80 PDK1 (0.59) PDK1PDK2PDK3PDK4NPC1
Hydrochloric Acid SCHEMBL28203570 0.79 PDK1 (0.68) PDK1PDK2PDK3PDK4NPC1
SCHEMBL28846032 0.79 PDK1 (0.67) PDK1PDK2PDK3PDK4NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960688-B2 Use of compounds for the elevation of pyruvate dehydrogenase activity ASTRAZENECA AB (SE) 2005-11-01 US disclosed
US-20040009979-A1 Use of compounds for the elevation of pyruvate dehydrogenase activity ZENECA LIMITED 2004-01-15 US disclosed
US-6498275-B1 Use of compounds for the elevation of pyruvate dehydrogenase activity ASTRAZENECA AB (SE) 2002-12-24 US disclosed
EP-1082110-A1 USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY AstraZeneca AB (SE) 2001-03-14 EP disclosed
WO-1999062506-A1 USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY ASTRAZENECA AB (SE) 1999-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009979-A1 Use of compounds for the elevation of pyruvate dehydrogenase activity PDHA1, PDK1, PDHB PDK1 2/4885PDK2 8/4885PDK3 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.